Emergent BioSolutions Inc.

NYSE:EBS 주식 보고서

시가총액: US$370.0m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Emergent BioSolutions 미래 성장

Future 기준 확인 0/6

Emergent BioSolutions 의 수익은 연간 0.4% 감소할 것으로 예상되는 반면, 연간 수익은 68.5% 로 증가할 것으로 예상됩니다. 68.5% 연간. EPS는 연간 69.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -13.6% 로 예상됩니다.

주요 정보

61.2%

수익 성장률

70.2%

EPS 성장률

Biotechs 수익 성장24.1%
매출 성장률-0.5%
향후 자기자본 수익률-13.6%
애널리스트 커버리지

Low

마지막 업데이트20 Jun 2024

최근 미래 성장 업데이트

Recent updates

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

May 10

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Dec 18

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Nov 23

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Aug 23

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Aug 14

Emergent BioSolutions: Making A Big Bet On Narcan

Jul 21

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

Emergent doses first participant in Phase 1 trial for Lassa virus vaccine

Sep 06

Emergent BioSolutions: Now Long Through Sale Of October Put Spreads

Aug 24

A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)

Aug 13
A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)

Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant

Aug 12

Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss

Aug 01

Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic

Jul 26

Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt

Jul 26
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt

Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig

Jul 06

Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak

May 29

Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate

May 12
Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate

수익 및 매출 성장 예측

NYSE:EBS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20261,143-112N/AN/A1
12/31/20251,138-11085691
12/31/20241,033-1562181692
3/31/20241,185-565-138-85N/A
12/31/20231,049-760-264-206N/A
9/30/20231,102-781-216-146N/A
6/30/20231,072-605-602-280N/A
3/31/2023974-394-523-181N/A
12/31/20221,118-212-394-34N/A
9/30/20221,49133-180201N/A
6/30/20221,58188127292N/A
3/31/20221,75715878279N/A
12/31/20211,77422096320N/A
9/30/20211,65322723237N/A
6/30/20211,709299121326N/A
3/31/20211,706387300483N/A
12/31/20201,577306385537N/A
9/30/20201,333167262413N/A
6/30/20201,259170184305N/A
3/31/20201,1086841141N/A
12/31/20191,1065591188N/A
9/30/20191,0164-181-100N/A
6/30/2019878-18-1577N/A
3/31/20198554266148N/A
12/31/201878263-3042N/A
9/30/2018706100221285N/A
6/30/201868111396146N/A
3/31/201856267119165N/A
12/31/201756183N/A208N/A
9/30/201751981N/A118N/A
6/30/201751268N/A110N/A
3/31/201750361N/A54N/A
12/31/201648963N/A55N/A
9/30/201649773N/A70N/A
6/30/201651294N/A148N/A
3/31/2016529125N/A153N/A
12/31/201548991N/A43N/A
9/30/201547879N/A93N/A
6/30/201545759N/A67N/A
3/31/201546035N/A76N/A
12/31/201440454N/A112N/A
9/30/201440022N/A69N/A
6/30/201435114N/A50N/A
3/31/201432419N/A72N/A
12/31/201331331N/A97N/A
9/30/201330932N/A49N/A

애널리스트 미래 성장 예측

수입 대 저축률: EBS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: EBS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: EBS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: EBS 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.4% ).

고성장 수익: EBS 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -0.4% ).

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: EBS (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y